Parker Waichman LLP Headlines by Topic
Aranesp
Sales of Potentially Dangerous Anemia Drugs Raise Questions
Jul 19, 2012
| Parker Waichman LLP
Three popular anemia drugs may have generated billions of dollars in revenue for two companies but they’ve proven to be dangerous and a drain...
FDA Says Another Safety Review of Anemia Drugs in the Works
Jan 7, 2010
| Parker Waichman LLP
Anemia drugs Procrit, Epogen and Aranesp are slated to undergo another safety review, following the publication of a clinical trail that linked one...
Procrit, Similar Drugs Linked to Increased Death Risk By Two More Studies
May 5, 2009
| Parker Waichman LLP
Two more studies have found that anemia drugs like Epogen, Procrit and Aranesp raise the risk of death among cancer patients. Despite known...
Amgen Ends Controversial Aranesp Marketing Practices
Aug 29, 2008
| Parker Waichman LLP
The maker of Aranesp is halting marketing practices that critics said encouraged over-use of the anemia drug. Criticism of the policies, in...
More than 44,000 Vials of Procrit Recalled
Aug 6, 2008
| Parker Waichman LLP
Procrit is being recalled by Johnson & Johnson subsidiary Ortho Biotech. According to the company's recall notice, the action is necessary...
FDA Forces New Labeling for Procrit, Aranesp and Epogen
Jul 31, 2008
| Parker Waichman LLP
Federal regulators have decided that the anemia drugs Aranesp, Epogen and Procrit need to have additional safety-related changes to their...
Study Says Genetic Tests May Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Jun 3, 2008
| Parker Waichman LLP
Some cancer patients treated with the anemia drugs Procrit, Aranesp and Epogen could experience increased tumor growth. However, researcher...
Congress Investigates Procrit, Epogen and Aranesp Marketing
Apr 2, 2008
| Parker Waichman LLP
Two members of Congress are looking into to allegations that the marketing of Procrit, Aranesp and Epogen encouraged overuse of the anemia drugs,...
Procrit, Aranesp, Epogen Should Be Allowed for Cancer Patients, With Some Restrictions, FDA Panel Says
Mar 13, 2008
| Parker Waichman LLP
An advisory panel has weighed in on the safety issues surrounding Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients and...
Procrit, Aranesp, Epogen Could be Restricted by FDA
Mar 12, 2008
| Parker Waichman LLP
Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients, could soon have new restrictions imposed on them by the Food and Drug...
ParkerWaichmanLLP
@ParkerWaichman
parkerwaichman
parkerwaichmanllp